Overview

A Multicenter Randomized Double-blind Placebo-controlled Pilot Study of Safety, Pharmacodynamics and Efficacy of Different Treatments of Immunotherapeutic Drug Mobilan (M-VM3) in Patients With Diagnosed Prostate Cancer

Status:
Unknown status
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
A Phase Ib2, multicenter, randomized, double-blind, placebo-controlled safety and efficacy study evaluating different regimens of the immunotherapeutic drug, Mobilan (M-VM3), in patients with prostate cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Panacela Labs LLC